Process for producing phenol, cresol and xylenes from a coal-derived feed are described. The processes combine dealkylation of alkylphenols from coal derived liquids followed by benzene and/or toluene transalkylation to reduce the production of non-ideal alkylbenzenes and reduce the usage of benzene/toluene. Alkylphenols from the coal derived liquids are converted in a dealkylation reaction zone comprising a dealkylation reactor to make phenol. The unconverted alkylphenols and an aromatic compound, such as benzene or toluene, are fed to a transalkylation reaction zone comprising a transalkylation reactor to make more phenol. Cresols and xylenes can also be produced.

Process for producing phenol, cresol and xylenes from a coal-derived feed are described. The processes combine dealkylation of alkylphenols from coal derived liquids followed by benzene and/or toluene transalkylation to reduce the production of non-ideal alkylbenzenes and reduce the usage of benzene/toluene. Alkylphenols from the coal derived liquids are converted in a dealkylation reaction zone comprising a dealkylation reactor to make phenol. The unconverted alkylphenols and an aromatic compound, such as benzene or toluene, are fed to a transalkylation reaction zone comprising a transalkylation reactor to make more phenol. Cresols and xylenes can also be produced.

The present invention relates to a method for producing cannabigerol and purifying it from a reaction mixture. The present invention also relates to the cosmetic use of cannabigerol for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, in particular for reducing pigmentation of the skin, preferably for the improvement of the appearance of the skin in case of hyperpigmentation, lentigo or vitiligo. Furthermore, the present invention relates to cannabigerol for use in a therapeutic method for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, preferably for use in a therapeutic method for the treatment and/or prevention of malign skin disorders, in particular skin cancer.

The present invention relates to a method for producing cannabigerol and purifying it from a reaction mixture. The present invention also relates to the cosmetic use of cannabigerol for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, in particular for reducing pigmentation of the skin, preferably for the improvement of the appearance of the skin in case of hyperpigmentation, lentigo or vitiligo. Furthermore, the present invention relates to cannabigerol for use in a therapeutic method for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, preferably for use in a therapeutic method for the treatment and/or prevention of malign skin disorders, in particular skin cancer.

The present invention relates to a method for producing cannabigerol and purifying it from a reaction mixture. The present invention also relates to the cosmetic use of cannabigerol for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, in particular for reducing pigmentation of the skin, preferably for the improvement of the appearance of the skin in case of hyperpigmentation, lentigo or vitiligo. Furthermore, the present invention relates to cannabigerol for use in a therapeutic method for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, preferably for use in a therapeutic method for the treatment and/or prevention of malign skin disorders, in particular skin cancer.

The present invention relates to a method for producing cannabigerol and purifying it from a reaction mixture. The present invention also relates to the cosmetic use of cannabigerol for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, in particular for reducing pigmentation of the skin, preferably for the improvement of the appearance of the skin in case of hyperpigmentation, lentigo or vitiligo. Furthermore, the present invention relates to cannabigerol for use in a therapeutic method for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, preferably for use in a therapeutic method for the treatment and/or prevention of malign skin disorders, in particular skin cancer.

The present disclosure relates to cannabigerol sulfonate esters of formula (1).

The present disclosure relates to cannabigerol sulfonate esters of formula (1).